Canada - français - Health Canada

accord healthcare inc - fingolimod (chlorhydrate de fingolimod) - capsule - 0.5mg - fingolimod (chlorhydrate de fingolimod) 0.5mg - immunomodulatory agents

Canada - français - Health Canada

jamp pharma corporation - fingolimod (chlorhydrate de fingolimod) - capsule - 0.5mg - fingolimod (chlorhydrate de fingolimod) 0.5mg - immunomodulatory agents

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - fingolimodum - capsules - fingolimodum 0.25 mg ut fingolimodi hydrochloridum, mannitolum, hydroxypropylcellulosum, hydroxypropylbetadexum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio 28 per centum pro capsula. - multiple sklerose - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

merck (schweiz) ag - cladribinum - comprimés - cladribinum 10.00 mg, hydroxypropylbetadexum, sorbitolum 64.04 mg, magnesii stearas, pro compresso. - multiple sklerose - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

biogen switzerland ag - fampridinum - retardtabletten - fampridinum 10 mg, cellulosum microcristallinum, hypromellosum, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, macrogolum 400, titanii dioxidum, pro compresso obducto. - multiple sklerose - synthetika

Canada - français - Health Canada

novartis pharmaceuticals canada inc - siponimod - comprimé - 0.25mg - siponimod 0.25mg - immunomodulatory agents

Canada - français - Health Canada

novartis pharmaceuticals canada inc - siponimod - comprimé - 2mg - siponimod 2mg - immunomodulatory agents

Union européenne - français - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod de chlorhydrate de - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunosuppresseurs - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Tunisie - français - Ministère de la Santé, Direction de l'inspection Pharmaceutique

taha pharma - fingolimod - gélule - 0.5 mg - antineoplasiques et immunomodulateurs - immunosuppresseurs - fingoline 0.5 est indiqué dans le traitement des adultes, adolescents et enfants à partir de 10 ans atteints de sclérose en plaques (sep) récurrente-rémittente (évoluant par poussées et rémissions) pour réduire la fréquence des poussées et ralentir la progression du handicap.

Canada - français - Health Canada

ascend laboratories ltd - fingolimod (chlorhydrate de fingolimod) - capsule - 0.5mg - fingolimod (chlorhydrate de fingolimod) 0.5mg - immunomodulatory agents